Search hospitals > Wisconsin > Marinette

Aurora Bay Area Medical Group-Marinette

Claim this profile
Marinette, Wisconsin 54143
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Recurrence
Conducts research for Lung Cancer
Conducts research for Ovarian Cancer
269 reported clinical trials
20 medical researchers
Photo of Aurora Bay Area Medical Group-Marinette in MarinettePhoto of Aurora Bay Area Medical Group-Marinette in MarinettePhoto of Aurora Bay Area Medical Group-Marinette in Marinette

Summary

Aurora Bay Area Medical Group-Marinette is a medical facility located in Marinette, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Recurrence, Lung Cancer, Ovarian Cancer and other specialties. Aurora Bay Area Medical Group-Marinette is involved with conducting 269 clinical trials across 368 conditions. There are 20 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Michael A Thompson.

Area of expertise

1Cancer
Global Leader
Aurora Bay Area Medical Group-Marinette has run 116 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Aurora Bay Area Medical Group-Marinette has run 47 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 negative
PR positive

Top PIs

Clinical Trials running at Aurora Bay Area Medical Group-Marinette

Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Prostate Cancer
Bladder Carcinoma
Squamous Cell Carcinoma
Renal Cell Carcinoma
Ovarian Cancer
Rectal Cancer
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Hormone Therapy with or without Radiation

for Breast Cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Aurora Bay Area Medical Group-Marinette?
Aurora Bay Area Medical Group-Marinette is a medical facility located in Marinette, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Recurrence, Lung Cancer, Ovarian Cancer and other specialties. Aurora Bay Area Medical Group-Marinette is involved with conducting 269 clinical trials across 368 conditions. There are 20 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Michael A Thompson.